Anon ; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 198 (abstract no. S.B.451).
Nordic Medical Research Council's HIV Therapy Study Group, Department of Infectious Diseases M 7431, Rigshospitalet, Copenhagen, Denmark
OBJECTIVE: To compare three doses of zidovudine. METHODS: Randomized, double-blind study of 400 mg, 800 mg, and 1200 mg zidovudine daily. All receive 3 capsules q.i.d. RESULTS: 478 patients in Scandinavia were enrolled between February 1, 1988, and December 31, 1989. Median follow-up till December 31 was 442 days. At admission, 27% had AIDS, 52% had current or previous HIV-related symptoms, and 21% had low CD4 cell counts (mostly below 200/mm3). Probable mode of transmission: homo- or bisexual 78%, heterosexual 14%, i.v. drugs 5%, transfusion 3%. Ninety-two percent were males. Pneumocystis carinii infection was reported for 15% at admission; during follow-up it occurred in 48 patients, 9 of which were relapses. Kaposi's sarcoma was reported for 25 patients initially and for a further 23 during the trial. Treatment was discontinued in 23% of the patients; the causes were: death 32%, side effects 29%, poor compliance 13%, wished open zidovudine or other anti-HIV drug 6%, wished no zidovudine at all 4%, other 16%. Blood transfusions were given to 18% of the patients, temporary treatment withdrawal was necessary in 26%. Forty-three patients have died. CONCLUSION: Based on an interim analysis, a data monitoring committee has recommended that the trial be continued.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- CD4 Lymphocyte Count
- Clinical Trials as Topic
- Double-Blind Method
- HIV Infections
- HIV Seropositivity
- Humans
- Male
- Scandinavia
- Zidovudine
Other ID:
UI: 102196264
From Meeting Abstracts